Delivering better treatments for neglected patients
DNDi’s objective is to deliver 16 to 18 new treatments for neglected patients by 2023.
Since 2003, DNDi has worked with its worldwide network of partners to:
- develop a new chemical entity – fexinidazole – into the first all-oral treatment for sleeping sickness
- develop 7 new treatments from existing molecules and recombining drugs to bring better treatments to patients for malaria, Chagas disease, leishmaniasis, and paediatric HIV
- initiate GARDP, a not-for-profit research and development organization developing and delivering new or improved antibiotic treatments